|
Open Orphan PLC - London-based pharmaceutical services - Swings to pretax profit of £277,000 in 202, from a loss of £11.0 million. Revenue rises 74% to £39.0 million from £22.2 million. Attributes growth to a record number of human challenge study contracts won throughout year. Order book grows 11% to £46 million of future contracted revenue as at December 31 from £41.6 million, year-on-year. Order book stands at £64.2 million on June 1. Says the revenue is expected to be recognised across 2022, 2023 and 2024. Confident in further growth in 2022. Looks forward to ‘converting its progress into value for shareholders.’
Current stock price: 14.84 pence, down 7.2% on Tuesday
12-month change: down 53%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
